LT3037089T - Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti - Google Patents

Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti

Info

Publication number
LT3037089T
LT3037089T LTEP16152447.5T LT16152447T LT3037089T LT 3037089 T LT3037089 T LT 3037089T LT 16152447 T LT16152447 T LT 16152447T LT 3037089 T LT3037089 T LT 3037089T
Authority
LT
Lithuania
Prior art keywords
eikozapentaenic
hypertriglycidemia
ethyl ester
acid ethyl
acid
Prior art date
Application number
LTEP16152447.5T
Other languages
English (en)
Inventor
Mehar Manku
Ian Osterloh
Pierre Wicker
Rene Braeckman
Paresh Soni
Original Assignee
Amarin Pharmaceuticals Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42102041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3037089(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amarin Pharmaceuticals Ireland Limited filed Critical Amarin Pharmaceuticals Ireland Limited
Publication of LT3037089T publication Critical patent/LT3037089T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LTEP16152447.5T 2009-02-10 2010-02-09 Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti LT3037089T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15129109P 2009-02-10 2009-02-10
US17375509P 2009-04-29 2009-04-29

Publications (1)

Publication Number Publication Date
LT3037089T true LT3037089T (lt) 2020-01-10

Family

ID=42102041

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP13156122.7T LT2596786T (lt) 2009-02-10 2010-02-09 Eikozapentaeno rūgšties etilo esterio naudojimas hipertriglicidemijai gydyti
LTEP16152447.5T LT3037089T (lt) 2009-02-10 2010-02-09 Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP13156122.7T LT2596786T (lt) 2009-02-10 2010-02-09 Eikozapentaeno rūgšties etilo esterio naudojimas hipertriglicidemijai gydyti

Country Status (23)

Country Link
US (29) US8293727B2 (lt)
EP (5) EP3037089B1 (lt)
KR (2) KR20140007973A (lt)
AU (1) AU2010213899B2 (lt)
BR (1) BRPI1007518A2 (lt)
CA (3) CA2751576C (lt)
CY (2) CY1122628T1 (lt)
DK (3) DK2596786T3 (lt)
ES (3) ES2769926T3 (lt)
HR (3) HRP20130811T1 (lt)
HU (1) HUE048299T2 (lt)
LT (2) LT2596786T (lt)
MX (1) MX2011008448A (lt)
NZ (1) NZ594395A (lt)
PH (1) PH12015500407B1 (lt)
PL (3) PL3037089T3 (lt)
PT (3) PT2596786T (lt)
RU (2) RU2505292C2 (lt)
SG (3) SG10201610916SA (lt)
SI (3) SI2596786T1 (lt)
SM (3) SMT202000079T1 (lt)
WO (1) WO2010093634A1 (lt)
ZA (1) ZA201105612B (lt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
PT2334295T (pt) 2008-09-02 2017-09-15 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica compreendendo ácido eicosapentanoico e ácido nicotínico e métodos de utilização dos mesmos
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
LT2376077T (lt) 2009-01-12 2017-08-10 Biokier Inc. Kompozicija ir būdas, skirti diabetui gydyti
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
US8293727B2 (en) 2009-02-10 2012-10-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
SI2424356T1 (en) 2009-04-29 2018-01-31 Armarin Pharmaceuticals Ireland Limited A stable pharmaceutical composition and procedures for its use
WO2010147994A1 (en) 2009-06-15 2010-12-23 Amarin Pharma, Inc. Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
CA2774616A1 (en) 2009-09-23 2011-03-31 Biokier, Inc. Composition and method for treatment of diabetes
MX2012003555A (es) 2009-09-23 2012-07-03 Amarin Corp Plc Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
WO2011087981A2 (en) 2010-01-15 2011-07-21 E. I. Du Pont De Nemours And Company Clinical benefits of eicosapentaenoic acid in humans
EP2542060B1 (en) * 2010-03-04 2019-10-02 Amarin Pharmaceuticals Ireland Limited Compositions for treating and/or preventing cardiovascular disease
NZ727980A (en) * 2010-11-29 2018-08-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (en) * 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
CN104321055A (zh) 2012-01-06 2015-01-28 翁特拉制药公司 游离酸形式的ω-3多不饱和脂肪酸的富含dpa组合物
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
US20150347716A1 (en) * 2012-02-14 2015-12-03 Photonz Corporation Ltd. Method for Supervising Consumption of a Medical Food for Prevention and/or Management of a Disease or Condition
US20130295173A1 (en) 2012-05-07 2013-11-07 Omthera Pharmaceuticals, Inc. Compositions of statins and omega-3 fatty acids
KR20200074259A (ko) 2012-05-15 2020-06-24 모치다 세이야쿠 가부시키가이샤 고혈중 고감도 c반응성 단백질 환자의 심혈관 질병 1차 예방제
US20130324607A1 (en) * 2012-06-05 2013-12-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypercholesterolemia
EP2861227A4 (en) 2012-06-17 2016-01-27 Matinas Biopharma Inc OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
WO2014004993A2 (en) * 2012-06-29 2014-01-03 Amarin Pharmaceuticals Ireland Limited Methods of reducing ldl-p
EP3815684B1 (en) 2012-06-29 2024-09-04 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US20140005265A1 (en) * 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating hypertriglyceridemia
US20140004183A1 (en) * 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating cardiovascular disease in statin-tolerant subjects
US9539230B2 (en) * 2012-09-28 2017-01-10 Mochida Pharmaceutical Co., Ltd. Composition for reducing new-onset diabetes
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US20140213648A1 (en) * 2012-12-31 2014-07-31 Amarin Pharmaceuticals Ireland Limited Methods of increasing epa blood levels
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140221452A1 (en) * 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and 5-htp and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US20140221358A1 (en) * 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and diazoxide and methods of use thereof
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
EP2968246A4 (en) * 2013-03-13 2016-08-03 Matinas Biopharma Inc OMEGA-3-PENTAIC ACID COMPOSITIONS AND METHODS OF USE
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
KR102039522B1 (ko) * 2013-06-03 2019-11-26 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. 근거리 무선 통신(ｎｆｃ)을 이용한 ｎｆｃ 태그의 기록방법 및 장치
US20140357717A1 (en) * 2013-06-04 2014-12-04 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
JP6804823B2 (ja) * 2013-10-14 2020-12-23 アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティーＡｒｉｚｏｎａ Ｂｏａｒｄ ｏｆ Ｒｅｇｅｎｔｓ ｏｎ ｂｅｈａｌｆ ｏｆ Ａｒｉｚｏｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ 白金錯体およびデバイス
US10561631B2 (en) * 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10547995B2 (en) * 2015-04-30 2020-01-28 Lg Electronics Inc. Method and device for transmitting/receiving data using Bluetooth mesh network
US10183044B2 (en) 2015-05-15 2019-01-22 P Tech, Llc Systems and methods for thrombosis prevention
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
WO2019084681A1 (en) 2017-10-30 2019-05-09 Montreal Heart Institute Methods of treating elevated plasma cholesterol
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
ES2983568T3 (es) 2018-09-24 2024-10-23 Amarin Pharmaceuticals Ie Ltd Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto
EP4010075A4 (en) * 2019-08-05 2023-11-15 Arrowhead Pharmaceuticals, Inc. Methods for the treatment of apoc3-related diseases and disorders
EP4058141A4 (en) 2019-11-12 2023-11-22 Amarin Pharmaceuticals Ireland Limited METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT WITH Atrial fibrillation and/or atrial flutter
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377526A (en) * 1981-05-15 1983-03-22 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid and its esters
CA1239587A (en) 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
US4526902A (en) * 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
JPS6135356A (ja) * 1984-07-27 1986-02-19 Nippon Oil & Fats Co Ltd 血液脂質脂肪酸の分析方法
US4920098A (en) * 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
US4843095A (en) 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IE63225B1 (en) * 1988-09-13 1995-04-05 Efamol Holdings Use of fatty acids in the treatment of myalgic encephalomyelitis
GB2223943A (en) 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
US4935243A (en) * 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
JP2839276B2 (ja) * 1989-01-23 1998-12-16 日本分光工業株式会社 超臨界流体抽出・分離方法及び装置
GB8906369D0 (en) 1989-03-20 1989-05-04 Tisdale Michael J Eicosapentaenoic acid
US5457130A (en) * 1989-03-20 1995-10-10 Cancer Research Campaign Technology Limited Eicosapentaenoic acid used to treat cachexia
CA2043615C (en) 1990-06-04 2001-08-14 Kazuhiko Hata Method of producing eicosapentaenoic acid or the ester derivative thereof
GB9012651D0 (en) * 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
JP3103588B2 (ja) 1990-11-16 2000-10-30 持田製薬株式会社 リポプロテイン（ａ）低下剤
SE9101642D0 (sv) 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
US5215630A (en) * 1991-06-04 1993-06-01 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation
AU2384292A (en) * 1991-07-30 1993-03-02 North Carolina State University Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
DE4133694C2 (de) * 1991-10-11 1993-10-07 Fresenius Ag Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
JP3400466B2 (ja) 1991-10-28 2003-04-28 日本水産株式会社 高純度エイコサペンタエン酸またはそのエステルの製造方法
JPH0649479A (ja) * 1992-07-28 1994-02-22 Maruha Corp ω−３不飽和脂肪酸系化合物の安定化法
GB9217780D0 (en) * 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
US5888541A (en) * 1992-08-21 1999-03-30 Scotia Holdings Plc Fatty acid treatment
GB9300125D0 (en) 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
WO1994028891A1 (en) 1993-06-04 1994-12-22 Martek Biosciences Corporation Method of treating coronary vascular disease using docosahexaenoic acid
GB9403857D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US5760081A (en) * 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
AU711482B2 (en) * 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
IT1274734B (it) * 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
GB9519661D0 (en) * 1995-09-27 1995-11-29 Scotia Holdings Plc Fatty acid treatment
WO1997039759A2 (en) 1996-04-24 1997-10-30 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
TW425285B (en) 1996-06-10 2001-03-11 Viva America Marketing Inc Fish oil and garlic nutritive supplement
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
ES2195175T3 (es) 1996-10-11 2003-12-01 Scarista Ltd Preparacion farmaceutica que comprende acido eicosapentaenoico y/o acido estearidonico.
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
EP1025842B1 (en) * 1997-10-30 2004-07-21 Morishita Jintan Co., Ltd. Double-leyered capsule of unsaturated fatty acid or derivative thereof and process for producing the same
KR100587551B1 (ko) 1997-12-10 2006-06-08 싸이클로스포린 테라퓨틱스 리미티드 오메가-3 지방산 오일을 함유하는 약학 조성물
US20020055529A1 (en) 1998-12-02 2002-05-09 Bisgaier Charles Larry Method for treating alzheimer's disease
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6193999B1 (en) * 1999-03-01 2001-02-27 Banner Pharmacaps, Inc. Gum acacia substituted soft gelatin capsules
ES2304061T3 (es) * 1999-07-28 2008-09-01 Swiss Caps Rechte Und Lizenzen Ag Preparado para el empleo como medicamento y/o para el complemento de articulos comestibles.
CA2382262C (en) * 1999-08-30 2004-12-07 Ocean Nutrition Canada Ltd. A nutritional supplement for lowering serum triglyceride and cholesterol levels
DE60022987T2 (de) 2000-05-22 2006-10-19 Pro Aparts - Investimentos E Consultoria Lda., Funchal Fettsäurezusammensetzung, die wenigstens 80 Gew.-% EPA und DHA enthält
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
JP2004506008A (ja) 2000-08-15 2004-02-26 ファイザー・プロダクツ・インク 治療コンビネーション
ITMI20010129A1 (it) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
GB0111282D0 (en) 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
US20020198177A1 (en) 2001-05-30 2002-12-26 Horrobin David Frederick Coenzyme Q and EPA
ITMI20012384A1 (it) * 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
ITMI20020269A1 (it) 2002-02-12 2003-08-12 Victorix Assets Ltd Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
HUP0200686A2 (hu) 2002-02-22 2003-09-29 EURO- "H" Beruházásszervezż és Ingatlanhasznosító Kft. Elektronikus berendezés és eljárás számsorozat eltalálására irányuló játékokban való részvételre kommunikációs berendezésen keresztül
US20030166614A1 (en) * 2002-03-01 2003-09-04 Harrison Stanley F. Method for reducing cholesterol and triglycerides
CA2390820A1 (en) * 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
US7314643B2 (en) * 2002-08-20 2008-01-01 Nikken Chemicals Co., Ltd. Soft capsule preparation
WO2004048497A1 (ja) * 2002-11-22 2004-06-10 Nippon Suisan Kaisha, Ltd. 高度不飽和脂肪酸、その塩、またはそのエステルを含有する外用組成物
GB0228079D0 (en) 2002-12-02 2003-01-08 Laxdale Ltd Huntington's Disease
AU2004216856A1 (en) 2003-03-05 2004-09-16 Solvay Pharmaceuticals Gmbh Use of omega-3-fatty acids in the treatment of diabetic patients
NZ541516A (en) 2003-03-18 2008-05-30 Novartis Ag Compositions comprising fatty acids and amino acids
ITMI20032247A1 (it) 2003-11-19 2005-05-20 Tiberio Bruzzese Interazione di derivati polari di composti insaturi con substrati inorganici
WO2005063231A2 (en) * 2003-12-31 2005-07-14 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
US7022713B2 (en) * 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent
WO2005114190A2 (en) * 2004-05-19 2005-12-01 Ppd Biomarker Discovery Sciences, Llc Methods of identifying biomarkers
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
ITRM20040395A1 (it) 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti Composizione comprendente statine e acidi grassi omega 3.
US7642287B2 (en) 2004-08-06 2010-01-05 Transform Pharmaceuticals, Inc. Statin pharmaceutical compositions and related methods of treatment
WO2006030753A1 (ja) 2004-09-13 2006-03-23 Santen Pharmaceutical Co., Ltd. 角結膜障害治療剤
CN1759834B (zh) * 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
EP2153824A1 (en) 2004-09-27 2010-02-17 Sigmoid Pharma Limited Seamless multiparticulate formulations
US20100021555A1 (en) 2004-10-15 2010-01-28 Karl Geiringer Compositions containing high omega-3 and low saturated fatty acid levels
FR2878747B1 (fr) 2004-12-03 2007-03-30 Pierre Fabre Medicament Sa Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
KR101356335B1 (ko) * 2004-12-06 2014-02-06 릴라이언트 파마슈티컬스 인코퍼레이티드 지질 치료를 위한 오메가-3 지방산 및 이상지질혈증 제제
US20070191467A1 (en) * 2004-12-06 2007-08-16 Reliant Pharmaceutical, Inc. Statin and omega-3 fatty acids for lipid therapy
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
GB2421909A (en) * 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
US20060189682A1 (en) * 2005-02-02 2006-08-24 Payne Joseph E Water soluble prodrugs of COX-2 inhibitors
EA200701913A1 (ru) 2005-03-08 2008-08-29 Релайэнт Фармасьютикалз, Инк. Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом
WO2007007686A1 (ja) * 2005-07-08 2007-01-18 Mochida Pharmaceutical Co., Ltd. 心血管イベント発症予防用組成物
RU2290185C1 (ru) * 2005-07-26 2006-12-27 Дмитрий Николаевич Мясников Композиция для нормализации липидного обмена и снижения массы тела и способ её получения
AU2006275784A1 (en) 2005-07-28 2007-02-08 Reliant Pharmaceuticals, Inc. Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
ITMI20051560A1 (it) 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
EP1948168A4 (en) 2005-10-28 2010-10-06 Numerate Inc COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND / OR HMG-COA REDUCTASE
US20070104779A1 (en) * 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
CA2628305C (en) 2005-11-11 2014-05-06 Mochida Pharmaceutical Co., Ltd. Jelly composition
EP2364701A1 (en) 2005-12-20 2011-09-14 Cenestra, Llc Omega-3 fatty acid formulations
ATE509624T1 (de) 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
CN102743755B (zh) * 2006-02-07 2015-01-14 持田制药株式会社 预防中风复发的组合物
WO2007128801A1 (en) 2006-05-08 2007-11-15 Novartis Ag Combination of organic compounds
EP2777701A1 (en) 2006-05-31 2014-09-17 Mochida Pharmaceutical Co., Ltd. Composition for preventing the occurrence of a cardiovascular event in multiple risk patient comprising the ethyl ester of all-cis-5,8,11,14,17-icosapentaenoic acid
US8877465B2 (en) 2006-07-05 2014-11-04 Photonz Corporation Limited Production of ultrapure EPA and polar lipids from largely heterotrophic culture
WO2008012329A2 (en) * 2006-07-28 2008-01-31 V. Mane Fils Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
EA018734B1 (ru) 2006-10-10 2013-10-30 Релайэнт Фармасьютикалз, Инк. СТАТИН И ОМЕГА-3 ЖИРНЫЕ КИСЛОТЫ ДЛЯ СНИЖЕНИЯ УРОВНЕЙ Apo-B
US20080125490A1 (en) * 2006-11-03 2008-05-29 My Svensson Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
US20080306154A1 (en) 2006-11-03 2008-12-11 My Svensson Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
CA2675836C (en) 2007-01-17 2016-10-11 Mochida Pharmaceutical Co., Ltd. Composition for preventing or treating thrombus- or embolus-associated disease
CA2677036A1 (en) 2007-03-06 2008-09-12 Bioriginal Food & Science Corp. Soft gelatin capsule shells containing oil soluble flavoring and methods of making the same
US20100119598A1 (en) 2007-06-29 2010-05-13 Takeda Pharmaceutical Company Limited Seamless capsule
US20090182049A1 (en) 2008-01-16 2009-07-16 Joar Arild Opheim Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
US20110118350A1 (en) 2008-05-20 2011-05-19 Mochida Pharmaceutical Co., Ltd. Composition for preventing cardiovascular event in high-risk patient
PT2334295T (pt) 2008-09-02 2017-09-15 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica compreendendo ácido eicosapentanoico e ácido nicotínico e métodos de utilização dos mesmos
US8293727B2 (en) 2009-02-10 2012-10-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
SI2424356T1 (en) 2009-04-29 2018-01-31 Armarin Pharmaceuticals Ireland Limited A stable pharmaceutical composition and procedures for its use
WO2010147994A1 (en) * 2009-06-15 2010-12-23 Amarin Pharma, Inc. Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
KR101579659B1 (ko) 2010-11-04 2015-12-22 에프. 호프만-라 로슈 아게 S-[2-([[1-(2-에틸부틸)-사이클로헥실]-카본일]아미노)페닐]2-메틸프로판티오에이트 및 크로스카멜로스 나트륨을 포함하는 조성물
US20140004183A1 (en) * 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating cardiovascular disease in statin-tolerant subjects

Also Published As

Publication number Publication date
RU2686315C2 (ru) 2019-04-25
US8293728B2 (en) 2012-10-23
US20130331447A1 (en) 2013-12-12
SMT201300095B (it) 2013-11-08
US20130171249A1 (en) 2013-07-04
CA2751576A1 (en) 2010-08-19
KR101383006B1 (ko) 2014-04-08
EP2596786A1 (en) 2013-05-29
EP3616694A1 (en) 2020-03-04
US8318715B2 (en) 2012-11-27
ES2769926T3 (es) 2020-06-29
US8415335B2 (en) 2013-04-09
US20110288171A1 (en) 2011-11-24
CA3008079A1 (en) 2010-08-19
AU2010213899A1 (en) 2011-08-25
CY1122629T1 (el) 2021-03-12
US20240024277A1 (en) 2024-01-25
US8314086B2 (en) 2012-11-20
SI2395991T1 (sl) 2013-12-31
US20130004567A1 (en) 2013-01-03
US20130171250A1 (en) 2013-07-04
MX2011008448A (es) 2012-02-28
KR20140007973A (ko) 2014-01-20
PT2596786T (pt) 2020-03-04
ZA201105612B (en) 2012-10-31
DK2395991T3 (da) 2013-09-02
EP2395991B1 (en) 2013-05-29
PL2395991T3 (pl) 2013-11-29
US20120108663A1 (en) 2012-05-03
SG10201610916SA (en) 2017-02-27
US20130005809A1 (en) 2013-01-03
SI3037089T1 (sl) 2020-03-31
US20120093924A1 (en) 2012-04-19
US20180185320A1 (en) 2018-07-05
PL2596786T3 (pl) 2020-06-01
US8357677B1 (en) 2013-01-22
ES2426132T3 (es) 2013-10-21
US8431560B1 (en) 2013-04-30
US20200246300A1 (en) 2020-08-06
EP2395991A1 (en) 2011-12-21
PL3037089T3 (pl) 2020-06-01
EP2596786B1 (en) 2019-11-27
US8399446B2 (en) 2013-03-19
US20130004568A1 (en) 2013-01-03
PH12015500407A1 (en) 2015-09-21
LT2596786T (lt) 2020-01-10
EP3037089A1 (en) 2016-06-29
CA3008079C (en) 2020-09-22
US8524698B2 (en) 2013-09-03
US20120108660A1 (en) 2012-05-03
HK1165698A1 (en) 2012-10-12
US8367652B2 (en) 2013-02-05
DK2596786T3 (da) 2020-02-24
US8426399B2 (en) 2013-04-23
US8293727B2 (en) 2012-10-23
SG173612A1 (en) 2011-09-29
EP3865128A1 (en) 2021-08-18
US20190038590A1 (en) 2019-02-07
US20210046036A1 (en) 2021-02-18
HRP20200068T1 (hr) 2020-04-03
US20120157530A1 (en) 2012-06-21
US8440650B1 (en) 2013-05-14
RU2013154780A (ru) 2015-06-20
PT2395991E (pt) 2013-09-03
AU2010213899B2 (en) 2014-02-06
CA3089847C (en) 2024-04-09
US20130164375A1 (en) 2013-06-27
US8518929B2 (en) 2013-08-27
US20120156285A1 (en) 2012-06-21
US20130102674A1 (en) 2013-04-25
US20120237594A1 (en) 2012-09-20
DK3037089T3 (da) 2020-01-20
RU2011137415A (ru) 2013-03-20
EP3037089B1 (en) 2019-11-27
HUE048299T2 (hu) 2020-07-28
CA2751576C (en) 2018-07-03
RU2505292C2 (ru) 2014-01-27
US20170119722A1 (en) 2017-05-04
BRPI1007518A2 (pt) 2018-02-20
US8324195B2 (en) 2012-12-04
HK1226307A1 (en) 2017-09-29
US20130004566A1 (en) 2013-01-03
US20130096197A1 (en) 2013-04-18
US20120039997A1 (en) 2012-02-16
NZ594395A (en) 2014-01-31
CA3089847A1 (en) 2010-08-19
HRP20200065T1 (hr) 2020-04-03
RU2019111131A (ru) 2020-10-15
SI2596786T1 (sl) 2020-03-31
PH12015500407B1 (en) 2015-09-21
WO2010093634A1 (en) 2010-08-19
US20100311834A1 (en) 2010-12-09
ES2768091T3 (es) 2020-06-19
HRP20130811T1 (en) 2013-09-30
PT3037089T (pt) 2020-03-04
US20130017256A1 (en) 2013-01-17
KR20110110321A (ko) 2011-10-06
US8546372B2 (en) 2013-10-01
SMT202000078T1 (it) 2020-03-13
US20210069142A1 (en) 2021-03-11
CY1122628T1 (el) 2021-03-12
US20120108659A1 (en) 2012-05-03
SMT202000079T1 (it) 2020-03-13
US8377920B2 (en) 2013-02-19
US20210251941A1 (en) 2021-08-19
SG10201400685SA (en) 2015-01-29

Similar Documents

Publication Publication Date Title
LT3037089T (lt) Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti
DK2623507T3 (da) Morpholinonukleinsyrederivat
BRPI1013937A2 (pt) compostos de ácido carboxílico
BRPI1009197A2 (pt) preparação de ácido alfa-cetopimélico
EP2442645A4 (en) choline
DK2421808T3 (da) 4-Hydroxysmørsyreanaloger
DK2562155T3 (da) Hydroxaminsyrederivat
DK2361256T3 (da) Cyclohexenyl-nukleinsyreanaloger
DOP2011000086A (es) Derivados de acido 1-amino-2-ciclobutiletilboronico
BRPI0913368A2 (pt) compostos de ácido carboxílico
IL214446A0 (en) Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
IL219314A0 (en) Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
EP2281080A4 (en) POLYLACTIC ACID FIBERS
HRP20190509T1 (hr) Spoj piridilaminooctene kiseline
EP2475761A4 (en) PHOTO BIOREACTOR
DK2234994T3 (da) Fedtsyre-butylester-blandinger
BRPI1011650A2 (pt) composições sólidas compreendendo ácido 5-aminolevulínico
EP2408299A4 (en) FATTY ACID MONOGLYCERIDE COMPOSITIONS
BRPI1009018A2 (pt) fotobiorreator
FR2952847B3 (fr) >
DOP2011000242A (es) Macrolido anti-inflamatorio
EP2542232A4 (en) FATTY ACID INHIBITORS
ITPD20090053U1 (it) Paradordi per banchine
BRPI1015272A2 (pt) Fermentação
GB0904300D0 (en) Essential fatty acid compounds